Pulsar-35 Self-Expanding Stent System

Indicated for use in patients with atherosclerotic disease of the femoral and proximal popliteal arteries, in particular for the treatment of insufficient results after Percutaneous Transluminal Angioplasty (PTA), e.g. residual stenosis and dissection.* *

Pulsar-35 product image

Product Highlights

People icon

140 μm thin struts

Pulsar-35 struts are thinner than the leading brands.1

Coating icon

Clinically Proven¤2,3

Long term safety and efficacy (24-month data), even in calcified lesions4,5

Arrow icon

Tri-axial delivery system

Accurate stent deployment6


Balloon catheter
Catheter type OTW
Recommended guide wire 0.035”
Stent material Nitinol
Strut thickness 140 μm
Strut width 85 μm
Stent coating proBIO™ (Amorphous Silicon Carbide)
Stent markers 6 gold markers each end
Sizes ø 5.0 - 7.0 mm; L: 30 - 200 mm
Proximal shaft 6F, hydrophobic coating
Usable length 90 and 135 cm


Stent

ø (mm)
Catheter length 90 cm

Stent length (mm)
6F 30 40 60 80 100 120 150 170 200
5 379878 379879 379880 379881 379917 379918 379919 379920 379921
6 379883 379884 379885 379886 379922 379923 379924 379925 379926
7 379888 379889 379890 379891 379927 379928 379929 379930 379931
Stent

ø (mm)
Catheter length 135 cm

Stent length (mm)
6F 30 40 60 80 100 120 150 170 200
5 379898 379899 379900 379901 379937 379938 379939 379940 379941
6 379903 379904 379905 379906 379942 379943 379944 379945 379946
7 379908 379909 379910 379911 379947 379948 379949 379950 379951

IFU Link

Refer to this IFU link for a copy of the Instructions for Use and for a complete listing of the indications, contraindications, warnings and precautions.

References:

*Indication as per IFU.
  1. Data on file. 6.0 mm diameters. Leading competitors have been selected based on the PV Stent Revenue Market Shares EU, 2017 and PV Revenue Market Shares APAC 2015; (Source: Millennium Research Group Inc.); 2. Bosiers M. et al. 4-French - compatible endovascular material is safe & effective in the treatment of femoropopliteal occlusive disease: Results of the 4EVER Trial. ENDOVASC THER 2013; 20: 746-756; 3. Lichtenberg M. Superficial Femoral Artery TASC D registry: 12-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2013 ; 54(4):433-9; 4. Lichtenberg et al. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions - the BIOFLEX PEACE All-Comers Registry.Vasa (2019), 1-9. doi_10.10240301-1526a0007853. 5. Bosiers M. 4EVER 24 month results: long-term results of 4F Pulsar stent in femoropopliteal lesions. Presented at: CIRSE 2013; Barcelona, Spain; 6. Data on file. ¤Clinical outcomes of Pulsar-18 can be used to illustrate clinical outcomes of Pulsar-35 due to identical stent platforms

Teleflex, the Teleflex logo, and proBIO and Pulsar are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S and/or other countries. All other names are the trademarks or registered trademarks of their respective owners. Refer to this IFU link for a copy of the Instructions for Use and for a complete listing of the indications, contraindications, warnings and precautions. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries.
© 2025 Teleflex Incorporated. All rights reserved.